Biological Products, (No Diagnostic Substances): what changed in each company's latest annual report

Of 10 Biological Products, (No Diagnostic Substances) companies with comparable revenue, 8 grew it and 2 saw it fall in their latest annual report. The median change was up 6.3%.

Biggest revenue gains

• Halozyme Therapeutics, Inc.Revenue up 37.6%
• Krystal Biotech, Inc.Revenue up 33.9%
• Neurocrine Biosciences IncRevenue up 21.4%
• Amgen Inc.Revenue up 10%
• Exelixis IncRevenue up 7%

Biggest revenue declines

• Moderna, Inc.Revenue down 39.9%
• BIO-TECHNE CorpRevenue down 0.4%

All 14 companies

• Amgen Inc.Net income up 88.5%
• Gilead Sciences, Inc.Net income up 1672.9%
• Moderna, Inc.Revenue down 39.9%
• Revolution Medicines, Inc.Total liabilities up 146.7%
• Biogen Inc.Net income down 20.8%
• Exelixis IncCash and cash equivalents up 122%
• Neurocrine Biosciences IncCash and cash equivalents up 206%
• Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%
• Repligen CorpCash and cash equivalents down 25.3%
• BIO-TECHNE CorpCash and cash equivalents up 63.2%
• Vaxcyte, Inc.Cash and cash equivalents down 55.2%
• Qiagen N.V.Net income up 408.3%
• Twist Bioscience CorporationTotal liabilities up 19.3%
• Krystal Biotech, Inc.Net income up 129.7%